From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Plazomicin structure.svg
IUPAC name
Other names
3D model (JSmol)
Molar mass 592.683 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Plazomicin (INN,[1] ZEMDRI) is a next-generation aminoglycoside ("neoglycoside") antibacterial derived from sisomicin by appending a hydroxy-aminobutyric acid (HABA) substituent at position 1 and a hydroxyethyl substituent at position 6'.[2][3]

Plazomicin has been reported to demonstrate in vitro synergistic activity when combined with daptomycin or ceftobiprole versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant S. aureus (VRSA) and against Pseudomonas aeruginosa when combined with cefepime, doripenem, imipenem or piperacillin/tazobactam.[3] It also demonstrates potent in vitro activity versus carbapenem-resistant Acinetobacter baumannii.[4]

In 2012, U.S. Food and Drug Administration granted fast track designation for the development and regulatory review of plazomicin.[5]

It is being developed by Achaogen, Inc. to treat serious bacterial infections due to multidrug-resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE)[6] and was in Phase III clinical trials as of April 7, 2016.[7]

In June 2018 the FDA approved plazomicin (ZEMDRI) for adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Enterobacter cloacae, in patients who have limited or no alternative treatment options. Zemdri is an intravenous infusion, administered once daily.[8][9] The FDA declined approval for treating bloodstream infections due to lack of effectiveness.[10]

See also[edit]


  1. ^ "WHO Drug Information, Vol. 26, No. 3, 2012. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 68" (PDF). World Health Organization. p. 314. Retrieved 27 April 2016.
  2. ^ Aggen, JB; Armstrong, ES; Goldblum, AA; Dozzo, P; Linsell, MS; Gliedt, MJ; Hildebrandt, DJ; Feeney, LA; Kubo, A; Matias, RD; Lopez, S; Gomez, M; Wlasichuk, KB; Diokno, R; Miller, GH; Moser, HE (30 August 2010). "Synthesis and Spectrum of the Neoglycoside ACHN-490" (PDF). Antimicrobial Agents and Chemotherapy. 54 (11): 4636–4642. doi:10.1128/AAC.00572-10. PMC 2976124. PMID 20805391. Retrieved 27 April 2016.
  3. ^ a b Zhanel, GG; Lawson, CD; Zelenitsky, S; Findlay, B; Schweizer, F; Adam, H; Walkty, A; Rubinstein, E; Gin, AS; Hoban, DJ; Lynch, JP; Karlowsky, JA (10 January 2014). "Comparison of the Next-Generation Aminoglycoside Plazomicin to Gentamicin, Tobramycin and Amikacin". Expert Review of Anti-infective Therapy. 10 (4): 459–73. doi:10.1586/eri.12.25. PMID 22512755.
  4. ^ García-Salguero, C; Rodríguez-Avial, I; Picazo, JJ; Culebras, E (October 2015). "Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?" (PDF). Antimicrobial Agents and Chemotherapy. 59 (10): 5959–66. doi:10.1128/AAC.00873-15. PMC 4576036. Retrieved 27 April 2016.
  5. ^ "Achaogen Announces Plazomicin Granted QIDP Designation by FDA". GlobeNewswire, Inc. Retrieved 27 April 2016.
  6. ^ "Achaogen — Plazomicin". Achaogen, Inc. Retrieved 27 April 2016.
  7. ^ "Plazomicin — AdisInsight". Springer International Publishing AG. Retrieved 27 April 2016.
  8. ^ "Medscape Log In". Retrieved 2018-07-03.
  9. ^ "BioCentury - FDA approves plazomicin for cUTI, but not blood infections". Retrieved 2018-06-28.
  10. ^ "Drugs@FDA: FDA Approved Drug Products". Retrieved 2018-06-28.